The most commonly reported side effects of reteplase include coronary artery stenosis, coronary artery disease, and ventricular fibrillation, based on 578 FDA adverse event reports from 2004 to 2025.
Percentages show how often each reaction appears relative to total reports for reteplase.
These are voluntary reports and do not establish that reteplase caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside reteplase. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
21.1% of reteplase adverse event reports involve female patients and 59.2% involve male patients. The largest age group is adult at 51%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking reteplase when the adverse event was reported.
Showing 15 of 26 indications
Reteplase is sold under the brand name Retavase.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.